Sign up Australia
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: SAExploration receives court approval to purchase Geokinetics’ assets

The assets listed in the agreement include machinery, seismic processing software and other equipment
Seismograph
The deal also includes certain contracts with exploration and production companies

SAExploration Holdings Inc (NASDAQ:SAEX) was a top gainer in the small-cap space. The energy company has been given the green light to proceed with the asset acquisition of Geokinetics Inc. The assets listed in the agreement include machinery, seismic processing software and other equipment. Certain contracts with exploration and production companies are also a part of the deal. Shares of the Texas-based company were up nearly 50% to US$2.49 in Friday morning trading.

Limelight Networks Inc (NASDAQ:LLNW) reported better-than-expected second-quarter results. The content delivery network surpassed analyst estimates on revenue and earnings, reporting fourth-consecutive quarter growth with an 11% revenue gain year-over-year. The Arizona-based company upped its yearly revenue guidance to a range of US$200mln to US$203mln from its previous guidance of US$198mln to US$202mln. Shares were up more than 10% to US$5.18.

READ: Dolphin Entertainment shares surge after signing famous faces and boosting revenue in its first quarter

Two of the top decliners of the day saw shares fall after news of a public offering.

Dolphin Entertainment Inc (NASDAQ:DLPN) will offer 2 million shares of its common stock priced at US$3 each. The digital content producer intends to use the US$6mln raised for general corporate purposes, including working capital. The content creator is also the parent company of 42West, a public relations and marketing services firm. Shares were down nearly 14% to US$3.04.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) also announced a public offering. The biotech will offer more than 4 million shares of its common stock priced at US$8 each. The US$32.5mln raised will go to the clinical development of its drug ZYN002. The cannabidiol treatment is being developed for patients with focal seizures. Shares of the Pennsylvania-based company fell nearly 30% to US$7.56.

The Russell 2000 small-cap index was down slightly in Friday morning trading.

View full DLPN profile View Profile

Dolphin Entertainment Inc Timeline

Related Articles

Lego
July 11 2018
From an almost standing start in 2016, the group is scheduled to run Bricklive banded shows at 60 venues this year
Email
February 13 2018
The shares are up 50% over the last year as the company's international expansion gains momentum
Throne of Glass
April 30 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use